Cannabis remains a controlled substance in most jurisdictions, but demand for medicinal and wellbeing cannabis products and their derivatives is growing fast.
As governments consider the public health and tax benefits, the cannabis market's potential reaches far beyond the simple growing and selling of the plant, promising to upend the status quo in several sectors.
DLA Piper launches global cannabis practice
Entrenched businesses in a wide range of industries – wellness, food and drink, energy, tobacco, pharmaceutical, even cosmetics and pet food – are racing to understand how cannabis products will affect their markets.
Executives must decide whether to acquire, partner with, or compete against new players. The cannabis market has a high regulatory burden – but offset by a potentially huge commercial payoff.
We're a leading player in this nascent industry. From start-up to private and public fundraisings, acquisition and business-critical compliance advice, we guide clients through the legal, regulatory and commercial issues.
We've seen several divergent streams materialising from the rapidly evolving regulation across the globe. Uncertainty and service gaps are appearing as the forces of innovation and disruption clash with the different maturity speeds of global regimes.
Our global Cannabis practice covers the full range of corporate, intellectual property, technology and R&D, employment, regulatory (particularly life sciences and financial) and litigation matters. We're advising in every segment of the pharmaceutical, biopharmaceutical, wellness and medicinal sectors around the world.
We help businesses plan for the compliance dragnet arising from the lack of geographical regulatory harmonisation. And we monitor regulatory changes across jurisdictions to guide clients on which countries they can do business in.
Our provision of legal services is limited to clients whose conduct is legal in the jurisdiction in question.